Advertisement

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris van Vliet, Pedro Farinha, Clare Gould, Simone Birch, Laurie H. Sehn, Vishakha Sovani, Mitchell Steven Ward, Bradley Augustson, Jorne Biccler, Joseph M. Connors, David W. Scott, Maher K. Gandhi, Kerry J. Savage, Tarec El-Galaly, Diego Villa and Chan Yoon Cheah

Article Figures & Data

Figures

Tables

  • Table 1.

    Patient characteristics by DE status, DH status, or other

    CharacteristicOther* (N = 171)DE (N = 33)DH (N = 7)P
    Age
     Median (range), y62 (19-89)62 (35-84)65 (44-77)
     >60 y96 (56)19 (58)4 (57)1.000
    Sex
     Male89 (52)11 (33)3 (43).128
    Stage at diagnosis
     I97 (57)26 (79)3 (43).030
     II74 (43)7 (21)4 (57)
    Poor performance status
     ECOG >124 (14)4 (12)0 (0).831
     LDH > ULN44 (31)10 (37)3 (50).418
     Extranodal sites–any91 (53)21 (64)3 (43).458
      >15 (3)0 (0)0 (0)
     Supradiaphragmatic103 (60)22 (67)3 (43).517
     Ki67, median (range)80 (15-100)82 (25-95)85 (40-90).337
     Bulk >7.5 cm33 (21)5 (18)4 (57).075
    COO
     GCB99 (65)13 (39)4 (57).019
     Non-GCB53 (35)20 (61)3 (43)
    Stage-modified IPI
     Low (0-1 point)71 (51)19 (73)3 (50).180
     Intermediate (2 points)41 (30)3 (12)1 (17)
     High (3-4 points)27 (19)4 (15)2 (33)
    • Unless otherwise noted, all data are n (%). Bold indicates statistically significant results.

    • ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; ULN, upper limit of normal.

    • * Sufficient IHC/FISH in 59 cases for full DH/DE assessment.

    • Excludes DH cases.

  • Table 2.

    EOT response

    DE (N = 32)DH (N = 6)Other (N = 160)
    CR285147
    PR206
    PD013
    Dead before assessment204
    • PD, progressive disease.

  • Table 3.

    Univariable and multivariable analysis

    Candidate factorUnivariable analysisMultivariable analysis
    PFSOSPFSOS
    HR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)P
    Age >60 y4.53 (1.99-10.28)<.0017.50 (2.63-21.35)<.0012.51 (0.51-12.42).259
    Male0.72 (0.39-1.34).3020.68 (0.34-1.34).268
    Elevated serum LDH2.21 (1.11-4.38).0232.43 (1.14-5.19).0140.98 (0.20-4.86).9761.54 (0.18-12.98).690
    Stage (II vs I)2.60 (1.39-4.90).0032.35 (1.19-4.63).0140.75 (0.16-3.62).7230.32 (0.04-2.85).304
    Extranodal sites1.07 (0.57-2.00).8311.16 (0.59-2.31).660
    Site (supra- vs infradiaphragmatic)1.01 (0.53-1.90).981.09 (0.55-2.18).800
    Ki670.85 (0.44-1.64).6220.88 (0.44-1.79).730
    Bulk disease2.10 (1.06-4.16).0332.05 (0.97- 4.32).063.67 (1.00-13.60).0503.69 (0.67-20.33).134
    COO0.63 (0.33-1.20).1590.55 (0.27-1.13).1030.94 (0.18-4.90).9370.58 (0.05-6.22).652
    DH1.21 (0.27-5.31).8040.61 (0.08-4.73).6391.34 (0.18-10.62).7530.68 (0.04-12.58).792
    DE1.27 (0.58-2.81).5521.40 (0.60-3.30).4391.58 (0.35-7.24).5551.92 (0.25-15.04).533
    Stage-modified IPI (n = 92)
     Low risk
     Intermediate risk2.95 (1.22-7.15).0202.57 (0.93-7.11).063
     High risk5.37 (2.29-12.62)<.0016.19 (2.43-15.77)<.001
    • Bold indicates statistically significant results.